Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Enlivex Therapeutics Ltd.

Enlivex ( ($ENLV) ) has issued an announcement. On September 25, 2026, Enlivex filed a Form 6-K with the U.S. Securities and Exchange Commission, f...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ENLV	$0.60	-1.35%	305.05K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ENLV	$0.60	-1.4%	305.05K
3
4
5
6

ENLV

Get Enlivex Therapeutics Ltd. Data in Excel

Get Enlivex Therapeutics Ltd. Data in Excel